Drug Profile
Complement C1 inhibitor protein - Takeda
Alternative Names: C1 esterase inhibitor - Baxter Healthcare; C1 esterase inhibitor - Hyland Immuno; C1 esterase inhibitor - Takeda; C1 Inattivatore Umano; C1 inhibitor - Hyland Immuno; C1 inhibitor - Takeda; Complement C1 esterase inhibitor - Baxter Healthcare; Complement C1 esterase inhibitor - Hyland Immuno; Complement C1 esterase inhibitor - TakedaLatest Information Update: 08 Dec 2021
Price :
$50
*
At a glance
- Originator Baxter International
- Developer Baxalta; Hyland Immuno
- Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Angioedema
- Discontinued Pancreatic disorders; Transplant rejection
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Jun 2016 Baxalta has been acquired and merged into Shire
- 19 Apr 2002 No development reported - Clinical-Phase-Unknown for Angioneurotic oedema in USA (IV-infusion)